Marvel Biosciences Corp. (MRVL.V)
0.18
+0.02
(+9.09%)
CAD |
TSXV |
Apr 02, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 11.39M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 38.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.5986 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 85.90% |
Profile
| Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. It develops several patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The company was founded on August 1, 2018 and is headquartered in Calgary, Canada. |
| URL | http://www.marvelbiotechnology.com |
| Investor Relations URL | https://marvelbiotechnology.com/investor-resources/ |
| HQ State/Province | Alberta |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Marvel Biosciences Corp. is a biotechnology company that utilizes a drug redevelopment approach to drug development. It develops several patented and patentable chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The company was founded on August 1, 2018 and is headquartered in Calgary, Canada. |
| URL | http://www.marvelbiotechnology.com |
| Investor Relations URL | https://marvelbiotechnology.com/investor-resources/ |
| HQ State/Province | Alberta |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |